sleep apnea tirzepatide FDA approves to treat Tirzepatide Reduces Apnea-Hypopnea Index in

The newer dual-action agent tirzepatide (Mounjaro) targets both GLP-1 and GIP receptors and is licensed in the UK for type 2 diabetes management

Whatever you make of these individual decisions, there should at least be a level of consistency here

So, while GLP-1 agonists could slightly lower sexual desire through brain chemistry, this effect is complex and can be masked by other benefits

doi: 10.1016/S2213-8587(19)30249-9 23 PilitsiEFarrOMPolyzosSAPerakakisNNolen-DoerrEPapathanasiouAEet al

What they did: They transected the quadriceps (front thigh) of rats and divided them into three groups: Control, no drugs Dexamethasone, a potent corticosteroid that is known to impair healing Dexamethasone + BPC-157 What they found: Dexamethasone group: 50 % worse healing than control (confirmed negative effect of steroids) Dexamethasone + BPC-157 group: healing at the level of controls without steroids Why it matters: This is a highly clinically relevant finding

My body needed the GLP-1 and clinical support, says Williams